Your Wegovy pen after 3 doses: what the titration schedule means for you

Where dose three sits in the STEP 1 trial design

The titration schedule for Wegovy is not arbitrary. In the STEP 1 trial (68 weeks, nearly 1,961 adults with obesity or overweight and a weight-related condition) participants followed a structured escalation from 0.25 mg up to the 2.4 mg maintenance dose before the active treatment phase was assessed. The STEP 1 paper, published in the New England Journal of Medicine, found an average body-weight reduction of around 15% at 2.4 mg over 68 weeks. That outcome was measured at a dose most participants took for the back half of the trial, not at the opener. Your third 0.25 mg injection is still in the preparatory phase. The prescriber-set schedule exists so that the medicine's GI effects build gradually, attempting to rush that process increases the likelihood of side effects severe enough to interrupt treatment.

A practical check you can do in under a minute: look at the dose indicator on your current pen before you inject. It should confirm you are on your third or fourth injection from this device. If you want to understand exactly what to expect at each stage of using your device, our guide to the Wegovy pen after 1 dose explains what the pen looks like and how it behaves from the very first injection. If the pen window shows empty before you expect it, contact your prescriber before using a new pen rather than assuming the next strength is correct.

What changes (and what stays the same) as you move past dose three

Physically, the pen does not change at dose three. You are still injecting once weekly, rotating between the abdomen, thigh or upper arm, following the same preparation steps each time. What shifts around this point for many people is tolerance: nausea and loose stools, which are the most commonly reported early effects, often begin to settle. The NHS medicines page for semaglutide notes that these effects are typically mild to moderate and tend to improve as treatment continues. That said, individual responses vary considerably. Some people feel very little in the first month; others find the step from 0.25 mg to 0.5 mg brings a fresh wave of nausea.

The dose after your final 0.25 mg injection is 0.5 mg, but only if your prescriber confirms that step is appropriate for you. Suitability is assessed at each stage. For a fuller picture of what each dose step involves, the Wegovy dose guide on this site covers the full titration ladder in detail. Your prescriber's clinical re-review before any repeat supply is what ensures each new strength is right for your current health picture.

Side effects to watch for around the third and fourth dose

Most people's GI symptoms peak in the first two to four weeks and then settle. The period around your third dose is therefore often when early discomfort begins to ease, not always, but commonly enough that the titration schedule was designed with this biology in mind. Common effects at this stage include nausea, indigestion, constipation or loose stools, and occasional headaches. These are well-documented in the semaglutide clinical programme and reflect the medicine's effect on gastric emptying and gut-hormone signalling. If you want a detailed breakdown of how the pen behaves and what symptoms to watch for at this specific point, our page covering the Wegovy pen after 2 doses walks through what most people experience as they approach their third injection.

Severe or persistent stomach pain, particularly if it radiates toward the back, warrants prompt medical attention rather than waiting to see if it passes. The MHRA highlighted acute pancreatitis as an infrequent but serious risk associated with GLP-1 medicines in a Drug Safety Update published in January 2026. Any suspected side effects can also be reported directly at the MHRA Yellow Card scheme. Keeping a brief note of how you feel in the days after each injection makes it easier to describe symptoms accurately to your prescriber at review.

People who are pregnant, breastfeeding or trying to conceive should not use Wegovy; the medicine is not licensed for use in pregnancy or for anyone under 18. If your circumstances change during treatment, contact your prescriber promptly. For broader context on treatment options and what private weight-loss programmes involve, the weight-loss treatment overview sets this out plainly.

What to do before your fourth dose and the pen change

Your fourth and final 0.25 mg dose completes the first pen, and if you want to know what to expect from the device at that point, our guide to the Wegovy pen after 4 doses covers how the pen should look and what happens next. Before ordering the next strength, a clinical review is needed, this is not a formality. A prescriber reads your update, considers any side effects you have reported, and confirms whether the step to 0.5 mg is appropriate. At nume, that review is carried out by a GPhC-registered Independent Prescriber; a real clinician reads your notes, not an automated system. Orders placed before 12pm on a working day are dispatched the same day once approved, arriving the next working day by tracked DPD delivery in plain packaging.

If you are considering starting Wegovy, or you are mid-treatment and thinking about how private clinical supervision works, you can read about Wegovy's full prescribing context before deciding. For those weighing up the cost of ongoing private treatment, the Wegovy access and cost page explains what a transparent private price typically covers. When you are ready to speak to our prescribers, checking your eligibility takes a few minutes and costs nothing.